RecruitingNot Applicable

Role of HbA1c in Predicting Adverse Pregnancy Outcomes

Malaysia195 participantsStarted 2024-06-27

Plain-language summary

This study aims to determine the reference value of HbA1c that can be used to predict adverse pregnancy outcomes. These adverse outcomes include LGA fetus, shoulder dystocia, caesarean section, pre-term birth, pre-eclampsia and fetal neonatal hypoglycaemia.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant woman with singleton pregnancy * Confirmed diagnosis of GDM based on Malaysia CPG (≥5.1/7.8) * HbA1c level taken at least once at any time during the pregnancy * Delivery after 28 weeks gestation Exclusion Criteria: * Major fetal anomaly * Haemoglobin level of ≤9 g/dL (moderate or severe anaemia in pregnancy) * Women with autoimmune diseases * Overt diabetes or pre-existing diabetes

What they're measuring

To determine the HbA1c reference value in predicting adverse pregnancy outcomes

Timeframe: Throughout study up to 1 year

Trial details

NCT IDNCT06676254

SponsorNational University of Malaysia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06-26

Contact for this trial

Rahana ARahman, MD

+60391455964 drrahana@ukm.edu.my

View on ClinicalTrials.gov More Gestational Diabetes trials